Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(03): 401-403
DOI: 10.4103/ijmpo.ijmpo_120_17
Practitioner Section

Rhabdomyosarcoma of the Iliopsoas: A Retroperitoneal Misdiagnosis

Animesh Ashutosh Upadhyay
Department of Surgery, Maharashtra University of Health Sciences, Nashik; Department of Surgery, Rajarshi Chhatrapati Shahu Maharaj, Government Medical College and Chhatrapati Pramila Raje General Hospital, Kolhapur, Maharashtra, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Rhabdomyosarcoma (RMS) is a rare soft tissue sarcoma. The already documented data regarding RMS state that it is more prevalent in males than females and also that its occurrence is more in Caucasians than Asians. The current incidence of RMS is 4.5 cases/million, and thus, it is a very rare cancer. The undifferentiated type is the most aggressive one with a rare presentation in the retroperitoneum. Overall, this case emphasizes that consideration should be given to wide range of diagnosis and that frozen section is the gold standard for a confirmatory diagnosis, as the first biopsy showed benign cells within the tumor. The emphasis on the interventions related to imaging to prevent the chance of aggravated presentation in the terminal stage of somatic comorbidities like loss of power. Radical excision of the mass along with normal iliopsoas tendon was done and referred to a cancer specialty center for further chemotherapy. To the best of my knowledge, this is the only case of RMS of the iliopsoas.

Keywords

Iliopsoas - pleomorphic - retroperitoneal - rhabdomyosarcoma


Publication History

Article published online:
04 July 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Perez EA, Kassira N, Cheung MC, Koniaris LG, Neville HL, Sola JE, et al. Rhabdomyosarcoma in children: A SEER population based study. J Surg Res 2011;170:e243-51.
  • 2 Ries LG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. National Cancer Institute (NCI), Bethesda, USA; 1999.
  • 3 Ognjanovic S, Linabery AM, Charbonneau B, Ross JA. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer 2009;115:4218-26.
  • 4 Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The third intergroup rhabdomyosarcoma study. J Clin Oncol 1995;13:610-30.
  • 5 Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, Donaldson SS, et al. The intergroup rhabdomyosarcoma study-II. Cancer 1993;71:1904-22.
  • 6 Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: An analysis of 2,600 patients. J Clin Oncol 2009;27:3391-7.
  • 7 Lim SM, Yoo CJ, Han JW, Cho YJ, Kim SH, Ahn JB, et al. Incidence and survival of pediatric soft tissue sarcomas: Comparison between adults and children. Cancer Res Treat 2015;47:9-17.
  • 8 Salunke AA, Shah J, Gupta N, Pandit J. Adult rhabdomyosarcoma: Multimodality management and results. J Cancer Res Ther 2017;13:384.